CAS: 105544-36-3; 7-Bromo-1H-Pyrido[2,3-B][1,4]Oxazin-2(3H)-One
该化合物是一个环环球化合物,其内装有七点方位溴替代体的引信丙烯-oxazine核心结构,该脚架对药用化学和药物研究具有重大兴趣,因为它具有作为合成生物活性分子的多种中间体的潜力.溴会增强反应性,通过交叉交错或核分裂替代反应进一步发挥作用.其硬性双环框架有助于分子稳定性和约束性互动的选择性,使其对发展酶抑制剂或受体调节器具有价值.该复合体的清晰结构和合成效用支持其在定向药物发现和机械研究中使用.
- 英文名称7-Bromo-1H-Pyrido[2,3-B][1,4]Oxazin-2(3H)-One
- 中文名称7-溴-1H-吡咯并[2,3-b][1,4]噁嗪-2(3H)-酮
- IUPAC名称7-bromo-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one
- 其它别名7 - 溴-1H-吡啶并[2,3-B] [1,4]恶嗪-2(3H) - 酮; 7-Bromo-1H-Pyrido[2,3-B][1,4]Oxazin-2-One
- CAS编号105544-36-3
- MFCD编号:MFCD01648627
- EINECS号:877-980-9
- 分子式:C7H5BrN2O2分子量:229.03
- 产品CID: 96542
- 产品分类有机原料→分子砌块→芳杂环类化合物→吡啶类化合物
相似化合物
1245708-13-7 136742-83-1 1313441-46-1物理性质
MSDS等安全信息
- GHS符号GHS07
- 危险类别急性毒性 类别4(吸入)
急性毒性 类别4(经皮)
急性毒性 类别4(经口)
特定目标器官毒性 - 单次接触 类别3
皮肤腐蚀/刺激 类别2
严重眼刺激 类别2A - 警示词Warning
- 危险描述H332 |吸入有害.
H312 |皮肤接触有害.
H302 |吞咽有害.
H335 |可能引起呼吸道刺激.
H315 |造成皮肤刺激.
H319 |造成严重眼刺激. - 防范说明P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
- 危险等级IRRITANT
- UN编号NONH for all modes of transport
- 危险品标志Xn
- 安全声明H303+H313+H333
- 危险类别码22
- WGK Germany3
欧盟法规
C&L通报合成工艺路线路线简述
📜5-溴-2-氯-3-硝基吡啶置于铁粉,Sodium Hydride,溶剂黄146体系中,用 四氢呋喃 用作溶剂,化学反应 1.0H,反应生成7-溴-1H-吡咯并[2,3-B][1,4]恶嗪-2(3H)-酮
参考文献:含恶嗪酮和噻嗪酮的双环杂芳醛的快速高效合成
标题:含恶嗪酮和噻嗪酮的双环杂芳醛的快速高效合成
摘要:摘要 描述了合成含恶嗪酮和噻嗪酮的双环杂芳醛的短而有效的路线,该路线涉及钯催化还原羰基化的关键步骤.合成这些醛的总体路线较短,用途广泛且可扩展,产品收率非常好.[本文提供补充材料.访问出版商的 Synthetic Communications® 在线版,获取以下免费补充资源:完整的实验和光谱细节.] 图形摘要
Doi:10.1080/00397911.2013.781183
专利信息
专利号:US-6017926-A
优先权日:1997-12-17
标题 :Integrin receptor antagonists
发明人：ASKEW BEN C; COLEMAN PAUL J; DUGGAN MARK E; HALCZENKO WASYL; HUTCHINSON JOHN H; MEISSNER ROBERT S; PATANE MICHAEL A; WANG JIABING
权利人:MERCK & CO INC
摘要:The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors alpha v beta 3, alpha v beta 5 and/or alpha v beta 6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, and tumor growth and metastasis.
专利号:EP-1040111-B1
优先权日:1997-12-17
标 题:Integrin receptor antagonists
发明人：DUGGAN MARK E; MEISSNER ROBERT S; HUTCHINSON JOHN H; HALCZENKO WASYL; ASKEW BEN C; COLEMAN PAUL J; PATANE MICHAEL A; WANG JIABING; PERKINS JAMES J
权利人:MERCK & CO INC
摘要:The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors alpha v beta 3, alpha v beta 5 and/or alpha v beta 6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, and tumor growth and metastasis.
专利号:US-6268378-B1
优先权日:1997-12-17
标题 :Integrin receptor antagonists
发明人：DUGGAN MARK E; MEISSNER ROBERT S; PERKINS JAMES J
权利人:MERCK & CO INC
摘要:The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the vitronectin receptors alphavbeta3 and/or alphavbeta5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.
